Table 1 Association between KIFs and prognosis of hepatobiliary carcinomas
From: The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside
KIFs | Subtribe | Cancer type | Expression | Data sources | Correlation with prognosis | References |
|---|---|---|---|---|---|---|
KIFC1 | Kinesin-14 A | HCC | Up-regulated | IHC staining performed with 82 tumor samples | High expression indicates poor OS (p = 0.011), RFS (p = 0.016), and is positively correlated with tumor size (p = 0.034) and lymph node status (p = 0.040) | [118] |
KIFC1 | Kinesin-14 A | HCC | Up-regulated | IHC staining of 168 tumor and 30 paired normal liver tissues | High expression correlates with poor survival outcomes (mean survival time: 45.57 months vs. 74.15 months, p < 0.002), including poor OS (p < 0.001), DFS (p < 0.001), and advanced tumor stage (p = 0.009), increased tumor size (p = 0.031) and recurrence hazard (p = 0.037) | [112] |
KIFC1 | Kinesin-14 A | HCC | Up-regulated | IHC staining of 91 paired HCC samples | Overexpression predicts a shorter TFS (p = 0.004), and closely correlates with tumor recurrence (p = 0.015) and metastasis (p = 0.001) | [119] |
KIFC1 | Kinesin-14 A | HCC | Up-regulated | RT-qPCR analysis of 101 paired HCC specimens | High expression indicates poor OS (p < 0.01), large tumor size (p = 0.0281), terrible differentiation (p = 0.0289), and elevated metastatic risk (p = 0.0085) | [113] |
KIF2C | Kinesin-13 | HCC | Up-regulated | IHC staining of 149 paired tumor and normal liver tissues | Overexpression predicts poor OS (p = 0.002), DFS (p = 0.021), and closely associates with tumor differentiation (p = 0.016) and recurrence (p = 0.025) | [107] |
KIFC3 | Kinesin-14B | HCC | Up-regulated | IHC staining of 36 paired HCC and adjacent normal samples | High expression correlates negatively with the OS (p = 0.037) | [114] |
KIF2A | Kinesin-13 | HCC | Up-regulated | IHC staining of 196 paired HCC samples | High expression drastically correlates with tumor size (p = 0.015), lymph node status (p = 0.018), BCLC stage (p < 0.001), and independently predicts poor OS (p = 0.001) | [120] |
KIF3B | Kinesin-2 | HCC | Up-regulated | IHC staining of 57 paired HCC specimens | Overexpression indicates poor OS (p < 0.010) and late histological grade (p < 0.01), and positively correlates with tumor size (p = 0.002), serum AFP levels (p = 0.041), as well as Ki-67 expression (p < 0.01) | [49] |
KIF4A | Kinesin-4 | HCC | Up-regulated | RT-qPCR analysis of 67 tumor and matched adjacent normal tissues | High expression predicts worse OS (p = 0.003), increased risk of recurrence (p = 0.0123) and metastasis (p = 0.022), as well as increased tumor size (p = 0.0143), T stage (p < 0.0001), and nodule status (p = 0.0029) | [69] |
KIF4A | Kinesin-4 | HCC | Up-regulated | IHC staining of 136 paired HCC samples | High expression positively correlates with poor OS (p < 0.001) and DFS (p = 0.0337) | [66] |
KIF4A | Kinesin-4 | HCC | Up-regulated | IHC staining of 211 paired HCC tissues | Overexpression distinctly correlates with poor OS (p = 2.81*10− 11), DFS (p = 4.99*10− 9), histological grade (p = 0.001), vascular invasion (p = 0.045), and TNM stage (p = 4.91*10− 7) | [67] |
KIF11 | Kinesin-5 | HCC | Up-regulated | RT-qPCR analysis of 108 paired primary HCC samples | High expression predicts poor OS (median OS: High-57.7 months, Median-75.3 months, Low-155.6 months, p = 0.002) and DFS (median DFS: High-39.4 months, Median-46.2 months, Low-126.3 months, p = 0.001) | [121] |
KIF11 | Kinesin-5 | HCC | Up-regulated | IHC staining of 156 paired HCC specimens | High expression negatively correlates with the OS (p = 2.43*10− 8) and TNM stage (p = 0.000151) | [122] |
KIF14 | Kinesin-3 | HCC | Up-regulated | RT-qPCR analysis of 102 paired HCC tissues | Overexpression indicates worse DFS (p < 0.001), advanced tumor stage (p = 0.013) and grade (p = 0.002) | [52] |
KIF15 | Kinesin-12 | HCC | Up-regulated | RT-qPCR analysis of 59 tumor and 49 paired peritumoral tissues | High expression independently predicts worse OS (p < 0.001), and significantly correlates with larger tumor size and inferior differentiation (p < 0.012, p < 0.040, respectively) | [123] |
KIF15 | Kinesin-12 | HCC | Up-regulated | RT-qPCR analysis of 120 paired HCC tissues | High expression associates with worse OS (p = 0.0004), increased recurrence hazard (p = 0.0011), as well as a close relationship with tumor size (p = 0.002), TNM stage (p < 0.001), vascular invasion (p < 0.001), tumor multiplicity (p = 0.013) and encapsulation status (p = 0.001) | [104] |
KIF18A | Kinesin-8 | HCC | Up-regulated | RT-qPCR analysis of 216 paired HCC tissues | High expression negatively correlates with the OS (Mean OS: high-39.26 months vs. low-55.06 months; p = 0.001) and DFS (Mean DFS: high-30.84 months vs. low-50.14 months; p = 0.001), and positively correlates with tumor size (p = 0.009), TNM stage (p < 0.001), and serum AFP levels (p = 0.030) | [124] |
KIF20A | Kinesin-6 | HCC | Up-regulated | IHC staining of 210 HCC samples (172 in pairs and 38 individual tumor specimens) | Overexpression predicts poor OS (p = 7.024*10− 6 ) and DFS (p = 1.634*10− 5), and notably correlates with tumor grade (p = 3.919*10− 5), TNM stage (p = 0.002), and vascular invasion (p = 0.005) | [83] |
KIF21B | Kinesin-4 | HCC | Up-regulated | IHC staining of 186 tumor and matched adjacent normal tissues | High expression predicts worse OS (p = 0.0002), DFS (p = 0.0005), TNM stage (p = 0.046), and vascular invasion (p = 0.012) | [70] |
KIF26B | Kinesin-11 | HCC | Up-regulated | IHC staining of HCC tissue microarrays containing 93 paired tumor samples | High expression indicates poor OS (p = 0.0145), and drastically correlates with late tumor stage and grade (p = 0.017, p = 0.004, respectively) | [102] |
KIF23 | Kinesin-6 | HCC | Up-regulated | IHC staining of 144 HCC tissues | Positive expression of KIF23 V1 predicts better 5-year OS (p = 0.0052) | [125] |
KIF1B | Kinesin-3 | HCC | No significant differences | WB and RT-qPCR analysis of 68 HCC and matched normal tissues | Down-regulation of KIF1B mRNA radios indicates worse OS (Median OS: downregulated-13.5 months vs. upregulated-20.0 months, p < 0.05) and DFS (Median DFS: downregulated-11.5 months vs. upregulated-19.5 months, p < 0.05) | [55] |
KIF10 | Kinesin-7 | HCC | Down-regulated | IHC staining of 90 paired HCC specimens | Decreased KIF10 expression associates with poor OS (p < 0.05), large tumor size (p = 0.038), advanced TNM stage (p = 0.009), and positive metastasis (p = 0.013) | [90] |
KIF18A | Kinesin-8 | CCA | Up-regulated | Proteomic analysis with plasma samples from induced hamster CCA models | Overexpression contributes to the early diagnosis | [136] |
KIF4A | Kinesin-4 | CCA | Up-regulated | RNA-seq and survival data from the GEO and GEPIA databases | High expression indicates poor OS (p = 0.035) | [137] |